Seth A. Wander, MD, PhD

Seth A. Wander, MD, PhD, is a medical oncologist at Massachusetts General Hospital. He serves as director of translational research for the Breast Oncology Program, where he leads a multidisciplinary team focused on leveraging genetic and molecular sequencing results to understand how cancers become resistant to standard therapies and to develop novel, personalized treatment strategies. As director of precision medicine for the Henri and Belinda Termeer Center for Targeted Therapies at the Mass General Brigham Cancer Institute, he leads efforts to promote novel and innovative research leveraging emerging genetic sequencing technologies to understand resistance to cancer therapies and to inform the design of new clinical trials. Finally, Dr Wander is an assistant professor of medicine at Harvard Medical School and remains engaged in teaching medical students, residents, and fellows.

Dr Wander completed his undergraduate degree at Cornell University, where he studied molecular and cell biology and graduated magna cum laude with distinction in research. He pursued his MD and PhD in cancer biology at the University of Miami. He completed his internship and residency in internal medicine at Massachusetts General Hospital and his fellowship training in medical oncology at Dana-Farber Cancer Institute and the Massachusetts General Hospital Cancer Center.

Dr Wander has clinical and translational research interests in breast cancer and cancer genomics. He has published more than 70 peer-reviewed articles in the field of precision medicine and continues to present educational sessions and original research related to drug resistance and the development of personalized therapy for breast cancer both nationally and internationally. Dr Wander's research has helped shape our understanding of drug resistance in metastatic breast cancer, and he continues to lead a variety of clinical trials, across all phases of drug development, focused on developing new personalized treatment options for patients with breast cancer.

He was a recipient of the 2017 Dana-Farber Cancer Institute Wong Family Translational Research Award and a 2018 Conquer Cancer Foundation (American Society of Clinical Oncology) Young Investigator Award.